JP2023109829A5 - - Google Patents

Download PDF

Info

Publication number
JP2023109829A5
JP2023109829A5 JP2023077065A JP2023077065A JP2023109829A5 JP 2023109829 A5 JP2023109829 A5 JP 2023109829A5 JP 2023077065 A JP2023077065 A JP 2023077065A JP 2023077065 A JP2023077065 A JP 2023077065A JP 2023109829 A5 JP2023109829 A5 JP 2023109829A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hydromorphone
average
buprenorphine
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023077065A
Other languages
English (en)
Japanese (ja)
Other versions
JP7797440B2 (ja
JP2023109829A (ja
Filing date
Publication date
Priority claimed from JP2019572473A external-priority patent/JP2020526500A/ja
Application filed filed Critical
Publication of JP2023109829A publication Critical patent/JP2023109829A/ja
Publication of JP2023109829A5 publication Critical patent/JP2023109829A5/ja
Priority to JP2025279707A priority Critical patent/JP2026053555A/ja
Application granted granted Critical
Publication of JP7797440B2 publication Critical patent/JP7797440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023077065A 2017-06-30 2023-05-09 治療方法及びその剤形 Active JP7797440B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025279707A JP2026053555A (ja) 2017-06-30 2025-12-24 治療方法及びその剤形

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762527337P 2017-06-30 2017-06-30
US62/527,337 2017-06-30
JP2019572473A JP2020526500A (ja) 2017-06-30 2018-06-29 治療方法及びその剤形
PCT/US2018/040460 WO2019006404A1 (en) 2017-06-30 2018-06-29 METHOD OF TREATMENT AND DOSAGE FORMS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019572473A Division JP2020526500A (ja) 2017-06-30 2018-06-29 治療方法及びその剤形

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025279707A Division JP2026053555A (ja) 2017-06-30 2025-12-24 治療方法及びその剤形

Publications (3)

Publication Number Publication Date
JP2023109829A JP2023109829A (ja) 2023-08-08
JP2023109829A5 true JP2023109829A5 (https=) 2024-01-30
JP7797440B2 JP7797440B2 (ja) 2026-01-13

Family

ID=64742714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019572473A Withdrawn JP2020526500A (ja) 2017-06-30 2018-06-29 治療方法及びその剤形
JP2023077065A Active JP7797440B2 (ja) 2017-06-30 2023-05-09 治療方法及びその剤形
JP2025279707A Pending JP2026053555A (ja) 2017-06-30 2025-12-24 治療方法及びその剤形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019572473A Withdrawn JP2020526500A (ja) 2017-06-30 2018-06-29 治療方法及びその剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025279707A Pending JP2026053555A (ja) 2017-06-30 2025-12-24 治療方法及びその剤形

Country Status (9)

Country Link
US (2) US12201629B2 (https=)
EP (1) EP3645000A4 (https=)
JP (3) JP2020526500A (https=)
KR (1) KR20200022026A (https=)
AU (1) AU2018291397A1 (https=)
BR (1) BR112019027889A2 (https=)
CA (1) CA3068036A1 (https=)
IL (1) IL271727A (https=)
WO (1) WO2019006404A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4568672A2 (en) * 2022-08-12 2025-06-18 Bioventures, Llc Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure
WO2026035694A1 (en) * 2024-08-05 2026-02-12 Adneuris Therapeutics, Inc. Cebranopadol useful for preventing or reducing opioid induced respiratory depression

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
ES2058111T3 (es) 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1997045091A2 (en) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
AU2003297074A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
SI1646328T1 (sl) 2003-07-25 2008-02-29 Euro Celtique Sa Zdravljenje pri odvajanju od odvisnosti
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
DE102005007859A1 (de) 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20070020339A1 (en) 2005-07-20 2007-01-25 Pharmorx Inc. Compositions and methods for controlling abuse of medications
JP2010509227A (ja) 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447013A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
JP2011506319A (ja) * 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
EP2262367A4 (en) 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
EP2254561A2 (en) 2008-03-26 2010-12-01 AllTranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
WO2011109743A2 (en) 2010-03-04 2011-09-09 Rand Jerry N Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
DE102010048883A1 (de) 2010-10-19 2012-04-19 Lars Holger Hermann Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen
HUE034955T2 (en) 2010-12-22 2018-03-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CN103547259A (zh) 2011-03-25 2014-01-29 普渡制药公司 控制释放药物剂型
US8933092B2 (en) 2011-05-31 2015-01-13 Qrxpharma Limited Methods and compositions comprising sequential administration opioid receptor agonists
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
KR102196741B1 (ko) 2012-04-17 2020-12-30 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
RU2012122945A (ru) 2012-06-04 2013-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Аналгетическое средство
TW201613590A (en) 2014-09-12 2016-04-16 Purdue Pharma Lp Systems and methods for attenuating opioid-induced euphoria
US9849124B2 (en) * 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Similar Documents

Publication Publication Date Title
DK168514B1 (da) Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet
JP2023109829A5 (https=)
JP2009102342A5 (https=)
JP2018520189A5 (https=)
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2014077003A5 (https=)
JP2017525718A5 (https=)
JP2009533457A (ja) Ｃ−ニトロソから誘導されるニトロキシル供与体
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JPWO2020250915A5 (https=)
JP2021514380A5 (ja) 筋障害及び骨障害を処置するための化合物及び組成物
EP4335509A3 (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
JP2020533402A5 (https=)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
CN115551515A (zh) 靶向3CLpro的连翘苷及其衍生物和抗新冠应用
IL316641A (en) Methods for treating Cushing's syndrome and liver disorders, and reducing liver toxicity from medications administered to the patient
JP2020526500A5 (https=)
JP2021091608A5 (https=)
CA2489705A1 (en) Use of amide derivative of ge 2270 factor a3 for the treatment of acne
CA2482687A1 (en) Treatment of mesothelioma
JP2019515052A5 (https=)
KR20080096829A (ko) 정맥내 항바이러스 치료
CN117243948A (zh) 包含瑞香素的组合物在制备风湿性关节炎药物中的应用
RU2657556C2 (ru) Антиспазматические 1,2-диолы и 1,2,3-триолы